Kindora
FeaturesSocial Impact InvestmentsPricing
AboutLive Demos
Sign InSign Up
    Kindora
    FeaturesSocial Impact InvestmentsPricing
    AboutLive Demos
    Sign InSign Up
    1. Home
    3. Foundations
    5. Kaleidoscope of Hope Foundation
    Kaleidoscope of Hope Foundation logo

    Kaleidoscope of Hope Foundation

    ActiveMedical Research
    MADISON, NJWebsite9736440500EIN: 22-3744037

    About Kaleidoscope of Hope Foundation

    The mission of the Kaleidoscope of Hope Ovarian Cancer Foundation is to raise funds for ovarian cancer research and increase awareness of the symptoms of this disease.

    Focus Areas

    ovarian cancer researchearly detectiontreatment researchcommunity grants for patients and familiesawareness and education

    Who They Fund

    patients with high‑grade serous ovarian cancer (HGSOC)patients with clear cell ovarian cancer (CCOC)patients undergoing chemotherapy / surgical resection whose tissue and blood are available for biomarker studies

    Funding Style

    project-specific research grantspreclinical/animal study support

    About Kaleidoscope of Hope Foundation

    Kaleidoscope of Hope Foundation Inc centers its giving on ovarian cancer research, with grants aimed at early detection, treatment research, and awareness. The foundation’s recent awards show a strong project-specific research pattern: a $50,000 grant to Women & Infant Hospital of Rhode Island supported work on spatially resolved immune responses to chemotherapy in high-grade serous ovarian cancer, while another $50,000 award to the Trustees of the University of Pennsylvania backed a p53-stabilizing treatment combination in TP53 wild type ovarian cancer. A separate $50,000 grant to Temple University supported study of CARM1 in cytokine-mediated antitumor response. The portfolio also reaches translational and biomarker work, including liquid biopsy research at University of Texas MD Anderson Cancer Center and a taurine-based ovarian cancer project at Stevens Institute of Technology. Alongside institutional research, the foundation also funds community support for people affected by ovarian cancer and their families. Its mission statement emphasizes both research funding and increasing awareness of symptoms, and the grant record reflects that dual emphasis through awards to investigators, medical centers, and patient-facing support.

    What Kaleidoscope of Hope Foundation Funds

    The foundation supports several distinct ovarian cancer research themes. In biomarker and translational work, it gave $25,000 to University of Texas MD Anderson Cancer Center for liquid biopsy research using extracellular vesicles to identify molecular predictors of disease patterns from matched tissue and blood. In treatment discovery, it awarded $50,000 to the Trustees of the University of Pennsylvania for an investigation of a p53-stabilizing targeted treatment combination in TP53 wild type ovarian cancer. It also funded $25,000 to Stevens Institute of Technology for a taurine-based study, described as testing whether nutritional taurine suppresses ovarian cancer. Another 2023 award of $25,000 to the Trustees of the University of Pennsylvania focused on clear cell ovarian cancer and combination DNA damage inhibitor strategies. The research topics point to a mix of early detection, experimental therapeutics, and subtype-specific biology.

    How Kaleidoscope of Hope Foundation Gives

    Typical grants cluster around $25,000 to $50,000, with a median of $25,000 and a 75th percentile of $50,000. The recent record includes repeated support for some recipients: University of Texas MD Anderson Cancer Center and the Trustees of the University of Pennsylvania each appear in more than one year, suggesting multi-year relationships rather than one-off awards. The foundation’s grant programs are research-oriented and include annual calls for proposals, with one program explicitly accepting unsolicited applications. It does not fund individuals directly through this research line, and the listed structure points to project-specific research support rather than unrestricted operating grants.

    Financial Snapshot

    Annual Giving

    $150K

    Total Assets

    $624K

    Total Revenue

    $181K

    Total Expenses

    $171K

    Typical Grant Size

    Most grants fall between $25K and $50K, with a median of $25K.

    25th Percentile

    $25K

    Median

    $25K

    75th Percentile

    $50K

    Geographic Reach

    Regional5 states funded

    About 14% of grants go to recipients in TX.

    Funding intensity
    Low
    High
    Headquarters

    Leadership

    EMILY DENAPOLI CO-PRES

    Accepts unsolicited proposals

    Deep Analysis

    Unlock Deep Analysis

    Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.

    Get Started Free

    Similar Funders

    See Similar Funders

    Free Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.

    Get Started Free

    Explore related grant guides

    Health GrantsHealth Grants in New JerseyGrants in New Jersey

    Want a Personalized Pitch for Kaleidoscope of Hope Foundation?

    Sign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.

    Get Started FreeView Pricing
    Free plan available
    No contracts
    Cancel anytime
    Free Weekly Newsletter

    The Grant Brief

    Weekly grant intelligence for social impact leaders. Curated opportunities, funding trends, and strategic insights — free.

    Join 500+ social impact leaders. Unsubscribe anytime. Privacy Policy

    Trusted by mission-driven teams at organizations nationwide

    Kindora Logo

    At Kindora, we combine data-driven insights with a human touch to create meaningful, strategic fundraising solutions for mission-driven organizations of all sizes.

    Get The Grant Brief — free weekly grant intelligence

    Quick Links

    • Features
    • Social Impact Investments
    • About Us
    • Mission
    • How It Works
    • Pricing
    • Sales deck
    • Philanthropy Jobs
    • Nonprofit Compensation
    • Live demo (every plan)
    • Individual prospecting demoBeta
    • Blog
    • FAQ
    • Getting Started

    Connect With Us

    LinkedInTwitterFacebook

    Find Grants

    Grants by CauseGrants by StateFoundations by CityEducation GrantsHealth GrantsArts & Culture GrantsEnvironment GrantsCommunity Development GrantsYouth Development Grants

    © 2026 Kindora. All rights reserved.

    Privacy PolicyTerms of ServiceSystem Status
    2 filings on record
    See If You're a Fit — FreeFree account · instant fit score · similar funders
    translational/clinical validation funding
    experimental therapeutics & biomarker development

    Topics

    high‑grade serous ovarian cancer biology and treatmentclear cell ovarian cancer therapeutic discoverytumor immunology and cytokine‑mediated antitumor responsesp53‑stabilizing targeted therapiesliquid biopsy/extracellular vesicle biomarker discovery for chemo responseimmune checkpoint markers longitudinal monitoring (LAG3, PD‑1, ICOS, OX40)combination DNA damage inhibitors + BET inhibitor strategiesnutritional compound (taurine) as anticancer agentCRISPR screens for novel therapeutic targets

    Where Kaleidoscope of Hope Foundation Makes Grants

    Grantmaking is regional and remains U.S.-based in the recent record, with all listed recent grants going to U.S. recipients. Texas appears as the top state by grant count, driven in part by awards to Houston-based University of Texas MD Anderson Cancer Center. New Jersey also appears in the grant record through Stevens Institute of Technology in Hoboken, while Pennsylvania receives support through Philadelphia-based University of Pennsylvania and Temple University. Recent awards also reach Providence, Rhode Island, showing that the foundation’s research funding extends beyond its headquarters state.

    Frequently Asked Questions About Kaleidoscope of Hope Foundation

    What kinds of projects does Kaleidoscope of Hope Foundation Inc fund?

    Its grants focus on ovarian cancer research, early detection, treatment research, awareness and education, and community grants for patients and families. Recent awards include immune-response studies, p53-targeted treatment research, liquid biopsy biomarker work, and a taurine-based ovarian cancer project.

    Does the foundation support more than one research project over time?

    Yes. The recent grant record shows repeat awards to University of Texas MD Anderson Cancer Center in 2023 and 2024, and to the Trustees of the University of Pennsylvania in both years as well. That pattern suggests ongoing support for selected research programs.

    What is the typical grant size?

    Typical awards are $25,000, with a median of $25,000 and a 75th percentile of $50,000. Recent grants in the record include both $25,000 and $50,000 awards.

    Can applicants submit unsolicited proposals?

    Yes for at least one active program. The KOH Research Grant Program and the KOH Research Grants (2025 research RFP) both state that applicants submit research proposals, and the program listing says they accept unsolicited applications.

    What geographic area does the foundation fund most often?

    Its giving is regional and U.S.-based in the recent grant record. Texas is the top state by grant count, followed by New Jersey and Pennsylvania in the listed awards.

    Latest 990 Filing

    2024

    Source: IRS Form 990-PF, fiscal year 2024.

    Open Grant Opportunities

    Current and upcoming funding from Kaleidoscope of Hope Foundation that your nonprofit may be able to apply for.

    Open nowCloses Nov 15, 2026

    KOH Research Grant Program (annual research proposals)

    Ovarian cancer researchTranslational researchEarly detection and therapeutics

    Who can apply: Researchers conducting ovarian cancer research. Specific eligibility details are provided in the annual Grant Application materials (contact kohgrantinfo@kohnj.org for questions).

    Deadline: Full proposals for 2025 are due by Tuesday, October 28, 2025. Notification by end of March 2026. Reporting deadlines for awarded grants include: half-year progress report and one-page budget by November 15, 2026; final report (3 pages narrative and final budget) by May 15, 2027.

    View & apply

    Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.

    Create a free account

    Deadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.

    Recent Grants

    Most recent grants reported to the IRS.

    RecipientLocationAmountYearPurpose
    TRUSTEES OF THE UNIVERISTY OF PENNSYLVANIAPHILADELPHIA, PA$50,0002024INVESTIGATION OF A NOVEL P53 STABILIZING TARGETED TREATMENT COMBINATION IN TP53 WILD TYPE OVARIAN CANCER.
    TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONNEW YORK, NY$50,0002024UNDERSTANDING THE ROLE OF CARM 1 IN REGULATION OF CYTOKINE-MEDIATED ANTITUMOR RESPONSE IN OVARIAN CANCER.
    UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTERHOUSTON, TX$25,0002024TO IDENTIFY LIQUID BIOPSY (EXTRACELLULAR VESICLES)BASED MOLECULAR PREDICTORS OF DISEASE PATTERNS FROM PATIENTS FROM MATCHED TISSUES AND BLOOD FROM PATIENTS WITH COMPLETE GROSS RESECTION AND PATIENTS WITH EXCELLENT AND POOR RESPONSE TO CHEMOTHERAPY, FOLLOWED BY CLINICAL VALLIDATION OF OUR FINDING IN PATIENTS WITH HIGHGRADE SEROUS OVARIAN CANCER.
    STEVENS INSTITUTE OF TECHNOLOGYHOBOKEN, NJ$25,0002024NUTRITIONAL SUPPLEMENT TAURINE SUPPRESSES OVARIAN CANCER.
    WOMEN & INFANT HOSPITAL OF RHODE ISLANDPROVIDENCE, RI$50,0002023DETERMINE SPATIALLY RESOLVED IMMUNE RESPONSES TO CHEMOTHERAPY IN HIGH GRADE SEROUS OVARIAN CANCER AND DETERMINE LEVELS OF SERUM LAG3, PD1, ICOS, AND OX40 THROUGHOUT THE COURSE OF CHEMOTHERAPY TREATMENT AND WHETHER THEY CORRELATE WITH PATIENT CLINICAL OUTCOMES.
    TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAPHILADELPHIA, PA$25,0002023CLEAR CELL OVARIAN CANCER (CCOC) IS OFTEN RESISTANT TO STANDARD OF CARE CHEMOTHERAPY AND HAS LIMITED TREATMENT OPTIONS. DR. XU IS IDENTIFYING EFFECTIVE TREATMENT OPTIONS FOR CCOC BY COMBINATION OF DNA DAMARGE INHIBITORS AND BET INHIBITOR, AND ALSO DISCOVERING NEW TARGETS BY CRISPR SCREEN. WITH THE SUPPORT FROM KOH FOUNDATION, DR. XU WILL BE ABLE TO HAVE SUPPLIES AND ANIMALS TO CONTINUE THE STUDY AND IDENTIFY EFFECTIVE THERAPEUTICS FOR CCOC.
    UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTERHOUSTON, TX$25,0002023TO IDENTIFY LIQUID BIOPSY (EXTRACELLULAR VESICLES)BASED MOLECULAR PREDICTORS OF DISEASE PATTERNS FROM PATIENTS FROM MATCHED TISSUES AND BLOOD FROM PATIENTS WITH COMPLETE GROSS RESECTION AND PATIENTS WITH EXCELLENT AND POOR RESPONSE TO CHEMOTHERAPY, FOLLOWED BY CLINICAL VALLIDATION OF OUR FINDING IN PATIENTS WITH HIGHGRADE SEROUS OVARIAN CANCER.

    TRUSTEES OF THE UNIVERISTY OF PENNSYLVANIA

    $50,000
    PHILADELPHIA, PA2024

    INVESTIGATION OF A NOVEL P53 STABILIZING TARGETED TREATMENT COMBINATION IN TP53 WILD TYPE OVARIAN CANCER.

    TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

    $50,000
    NEW YORK, NY2024

    UNDERSTANDING THE ROLE OF CARM 1 IN REGULATION OF CYTOKINE-MEDIATED ANTITUMOR RESPONSE IN OVARIAN CANCER.

    UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

    $25,000
    HOUSTON, TX2024

    TO IDENTIFY LIQUID BIOPSY (EXTRACELLULAR VESICLES)BASED MOLECULAR PREDICTORS OF DISEASE PATTERNS FROM PATIENTS FROM MATCHED TISSUES AND BLOOD FROM PATIENTS WITH COMPLETE GROSS RESECTION AND PATIENTS WITH EXCELLENT AND POOR RESPONSE TO CHEMOTHERAPY, FOLLOWED BY CLINICAL VALLIDATION OF OUR FINDING IN PATIENTS WITH HIGHGRADE SEROUS OVARIAN CANCER.

    STEVENS INSTITUTE OF TECHNOLOGY

    $25,000
    HOBOKEN, NJ2024

    NUTRITIONAL SUPPLEMENT TAURINE SUPPRESSES OVARIAN CANCER.

    WOMEN & INFANT HOSPITAL OF RHODE ISLAND

    $50,000
    PROVIDENCE, RI2023

    DETERMINE SPATIALLY RESOLVED IMMUNE RESPONSES TO CHEMOTHERAPY IN HIGH GRADE SEROUS OVARIAN CANCER AND DETERMINE LEVELS OF SERUM LAG3, PD1, ICOS, AND OX40 THROUGHOUT THE COURSE OF CHEMOTHERAPY TREATMENT AND WHETHER THEY CORRELATE WITH PATIENT CLINICAL OUTCOMES.

    TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

    $25,000
    PHILADELPHIA, PA2023

    CLEAR CELL OVARIAN CANCER (CCOC) IS OFTEN RESISTANT TO STANDARD OF CARE CHEMOTHERAPY AND HAS LIMITED TREATMENT OPTIONS. DR. XU IS IDENTIFYING EFFECTIVE TREATMENT OPTIONS FOR CCOC BY COMBINATION OF DNA DAMARGE INHIBITORS AND BET INHIBITOR, AND ALSO DISCOVERING NEW TARGETS BY CRISPR SCREEN. WITH THE SUPPORT FROM KOH FOUNDATION, DR. XU WILL BE ABLE TO HAVE SUPPLIES AND ANIMALS TO CONTINUE THE STUDY AND IDENTIFY EFFECTIVE THERAPEUTICS FOR CCOC.

    UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

    $25,000
    HOUSTON, TX2023

    TO IDENTIFY LIQUID BIOPSY (EXTRACELLULAR VESICLES)BASED MOLECULAR PREDICTORS OF DISEASE PATTERNS FROM PATIENTS FROM MATCHED TISSUES AND BLOOD FROM PATIENTS WITH COMPLETE GROSS RESECTION AND PATIENTS WITH EXCELLENT AND POOR RESPONSE TO CHEMOTHERAPY, FOLLOWED BY CLINICAL VALLIDATION OF OUR FINDING IN PATIENTS WITH HIGHGRADE SEROUS OVARIAN CANCER.